Jibeier Pharm, headquartered in Zhenjiang, Jiangsu Province, reported that its filing to IPO on the new Science and Technology Innovation Board has been accepted for review by the Shanghai Stock Exchange. The company expects to raise $100 million in the offering. Jibeier plans to use the funds to build a new drug manufacturing facility and R&D center, and to support its R&D of new drugs along with clinical trials. Founded in 2001, Jibeier makes chemical drugs, TCM products and APIs.
Source: China Biotoday
